June 7, 2024 Epicrispr Biotechnologies to Present IND-Enabling Data Package for EPI-321 at FSHD International Research Congress
May 23, 2024 Epicrispr Biotechnologies to Participate in Fireside Chat at Stifel’s Genetic Medicines Forum
April 23, 2024 Epicrispr Biotechnologies Presents New Data Highlighting Potential of EPI-321 for FSHD and Epigenetic Editing Platform Leadership at ASGCT Annual Meeting
April 10, 2024 Epicrispr Biotechnologies to Participate in a Fireside Chat Titled Genetic Medicine for Generalists Hosted by Canaccord
April 9, 2024 Epicrispr Biotechnologies Announces Robust Slate of Presentations at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
April 1, 2024 Epicrispr Biotechnologies to Participate in a Fireside Chat at the Cantor Virtual Muscular Dystrophy Symposium
March 13, 2024 Epicrispr Biotechnologies to Present at the Upcoming Charles River Cell and Gene Therapy Summit
November 16, 2023 FDA Grants Orphan Drug Designation to EPI-321, Epicrispr Biotechnologies’ Novel Genetic Medicine Candidate for Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
October 31, 2023 Kite and Epicrispr Biotechnologies Announce Collaboration to Develop New Cell Therapies for Cancer
October 26, 2023 Epicrispr Biotechnologies Reports New Data on Hypercompact Cas Proteins Optimized for Broad Therapeutic Applicability
